ACRPO  >> Vol. 6 No. 1 (January 2017)

    甲磺酸阿帕替尼治疗一例肺腺癌脑转移患者的疗效分析
    Analysis of the Efficacy of Apatinib in the Treatment of Brain Metastases of Lung Adenocarcinoma

  • 全文下载: PDF(640KB) HTML   XML   PP.1-8   DOI: 10.12677/ACRPO.2017.61001  
  • 下载量: 1,052  浏览量: 3,624  

作者:  

祝金龙,王 红:解放军第307医院肺部肿瘤科,北京

关键词:
甲磺酸阿帕替尼非鳞非小细胞肺癌晚期肺癌Apatinib Non-Small-Cell Lung Cancer Advanced Lung Cancer

摘要:

肺癌是世界上最常见也是恶性程度最高的恶性肿瘤之一,其致死率高居各类恶性肿瘤之首,五年生存率不足20%,其中非小细胞肺癌占其中70%以上,发现时多为晚期,非小细胞肺癌的5年生存率不足6%,患者可以通过选择放化疗得到疾病缓解和生存获益,仍有大部分患者会在末次化疗后的2到3个月内再次出现疾病的进展,特别是对于基因检测阴性的患者,对针对应用此类基因的靶向药物疗效不佳,研究发现新生血管为肿瘤生长提供氧和营养,促进肿瘤的生长,而血管内皮生长因子(VEGF)能激活下游通路刺激血管通过结合血管内皮细胞增生的表皮生长因子受体(VEGFR),从而导致肿瘤的生长,抗血管生成药物通过抑制抑制血管生成能够抑制肿瘤发生发展和转移,甲磺酸阿帕替尼属于小分子抗血管生成抑制剂,作用于血管表皮生长因子酪氨酸激酶受体,通过抗血管生成来抑制实体肿瘤生长,甲磺酸阿帕替尼对于多线治疗失败的的非小细胞肺癌晚期治疗优确切的疗效,具有较好的耐受性。本文报道1例甲磺酸阿帕替尼作为四线药物治疗晚期非鳞NSCLC脑转移患者。

Lung cancer is one of the world’s most common and most malignant tumors. The lethality rate of which is the highest in all types of malignant tumors. The five-year survival rate of it is less than 20%, non-small cell lung cancer accounting for more than 70% of all cases and being diagnosed in the locally advanced stage. The 5-year survival rate of NSCLC is less than 6%. Patients can get relief and survival benefit by chemotherapy. Most patients will get PD in 2 or 3 months after the last chemotherapy, especially for those with negative genetic testing showing dismal efficacy to the application of molecular targeted drugs. Study found that neovascularization provide oxygen and nutrition for the growth of the tumor, to promote its growth. Anti-angiogenic drugs can inhibit tumor from progressing and metastasis by inhibiting angiogenesis. And the vascular epidermal growth factor (VEGF) can activate the downstream pathway to stimulate the proliferation of vessel endothelium via binding vascular epidermal growth factor receptor (VEGFR), thus leading to the growth of tumor. Paclitaxel mesylate is a small molecular anti-angiogenesis inhibitor. It can inhibit solid tumor growth factor tyrosine kinase receptor. Acid apatinib shows excellent efficacy and good tolerance for the advanced NSCLC whose multi-line treatment has been failed. This paper reports a case of apatinib mesylate as a fourth-line drug treatment in patients with advanced non-squamous NSCLC brain metastases.

文章引用:
祝金龙, 王红. 甲磺酸阿帕替尼治疗一例肺腺癌脑转移患者的疗效分析[J]. 亚洲肿瘤科病例研究, 2017, 6(1): 1-8. https://doi.org/10.12677/ACRPO.2017.61001

参考文献

[1] Mok, T., et al. (2014) A correlate Ⅳ Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemo Therapy for Advanced Non-Squamous Non-Small-Cell Lung Cancer: Results of the Phase 2 Randomized ABIGAIL Study. Journal of Thoracic Oncology, 9, 848-55.
[2] Zhou, C., et al. (2015) BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent NonSquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33, 2197-2204.
https://doi.org/10.1200/JCO.2014.59.4424
[3] Reck, M., et al. (2014) Docetaxel Plus Nintedanib versus Docetaxel Plus Placebo in Patients with Previously Treated Non-Small-Cell Lung Cancer (LUME-Lung 1). A Phase 3, Double-Blind, Randomized Controlled Trial. Lancet Oncology, 15, 143-155.
https://doi.org/10.1016/S1470-2045(13)70586-2
[4] Seto, T., et al. (2014) Erlotinib Alone or with Bevacizumab as First-Line Therapy in Patients with Advanced Non-Squamous Non-Small-Cell-Lung Cancer Harbouring EGFR Mutations (J025567): An Open-Label Randomised, Multicentre, Phase 2 Study. Lancet Oncology, 15, 1236-1244.
https://doi.org/10.1016/S1470-2045(14)70381-X
[5] Sandler, A., et al. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550.
https://doi.org/10.1056/NEJMoa061884
[6] Reck, M., et al. (2009) Phase 3 Trial of Cisplatin Plus Gemcitabine with Either Placebo or Bevarizumab as First-Line Therapy Fornonsquamous Non-Small-Cell Lung Cancer: AVAil. Journal of Clinical Oncology, 27, 1227-1234.
https://doi.org/10.1200/JCO.2007.14.5466
[7] Patel, J. D., et al. (2013) Point Break: A Randomized Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumah Followed by Maintenance Pemetrexed and Bevacizumah versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage 3 B or 4 Non-Squamousnon-Small-Cell Lung Cancer. Journal of Clinical Oncology, 31, 4349-4357.
https://doi.org/10.1200/JCO.2012.47.9626
[8] Garon, E.B., et al. (2014) Ramucirumab Plus Docetaxel versus Placebo Plus Docetaxel for Second-Line Treatment of Stage 4 Non-Small-Cell Lung Cancer after Disease Progression on Platinum-Based Therapy (REVEL): Amulti Centre, Double-Blind, Randomized Phase 3 Trial. Lancet, 384, 665-673.
https://doi.org/10.1016/S0140-6736(14)60845-X
[9] Barlesi, F., et al. (2013) Randomized Phase 3 Trial of Maintenance Bevacizumab with or without Pemetrexed after First-Line Induction with Bevacizumab, Cisplatin, and Pemetrexed Inadvanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (M022089). Journal of Clinical Oncology, 31, 3004-3011.
[10] Lynch, T.J., el al. (2014) Safety and Effect 4 Eness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer : Final Results of the ARIES Observational Cohort Study. Journal of Thoracic Oncology, 9, 1332-1339.
[11] Crino, L., et al. (2010) Safety and Efficacy of First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (SAiL, M019390): A Phase 4 Study. Lancet Oncology, 11, 733-740.
https://doi.org/10.1016/S1470-2045(10)70151-0
[12] Heist, R.S., et al. (2008) VEGF Polymorphisms and Survival 4 in Early-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 856-862.
https://doi.org/10.1200/JCO.2007.13.5947